Nashville, Tenn.-based Vanderbilt Health recorded an operating income of $249.7 million (5.4% operating margin) in the first half of fiscal 2026, up from an operating income of $130.1 million (3.1% margin) during the same period last year, according to its Feb. 27 earnings report.
Vanderbilt Health reported total operating revenue of $4.7 billion for the six months ended Dec. 31, up from $4.2 billion during the same period last year. The system’s 14% growth in patient service revenue was the key driver of the increase. Net patient service revenue was $4.1 billion, up from $3.6 billion. This increase was attributed to favorable realization/collections, CMI/acuity, payer mix and volumes.
Total operating expenses were $4.4 billion in the first half of 2026, up from $4 billion last year. Salaries, wages and benefits were $2.3 billion, up from $2.1 billion. Supplies and drug expenses were $1.1 billion, up from $989.5 million. Vanderbilt said the increase in drug costs was driven by growth in its retail and specialty pharmacy, as well as utilization of certain higher-cost drugs in the clinical setting. Supply expenses were driven by surgical volumes and higher-acuity surgeries, such as transplants.
Vanderbilt Health reported a net income of $361 million in the first half of 2026, up from $203.9 million in the first half of 2025.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
